A Versatile Adeno-Associated Virus Vector Producer Cell Line Method for Scalable Vector Production of Different Serotypes by Yuan, Zhenhua et al.
A Versatile Adeno-Associated Virus Vector Producer
Cell Line Method for Scalable Vector Production
of Different Serotypes
Zhenhua Yuan,* Chunping Qiao,* Peiqi Hu, Juan Li, and Xiao Xiao
Abstract
Application of adeno-associated virus (AAV) vector in large animal studies and clinical trials often requires high-
titer and high-potency vectors. A number of currently used vector production methods, based on either transient
transfection or helper virus infection of cell lines, have their advantages and limitations. We previously devel-
oped a 293-cell–based producer cell line method for high-titer and high-potency AAV2 vectors. Similar to several
other methods, however, it requires multiple cloning steps for the vector and packaging plasmids and a two-step
transfection and selection for stable cell lines. Here we report a simplified method with several key improve-
ments and advantages: (1) a one-step cloning of AAV vector cassette into the serotype-specific packaging
plasmid; (2) a single plasmid transfection and selection for stable AAV vector producer cell lines; (3) high vector
yields of different serotypes, e.g., AAV2, 8, and 9, upon infection with an E1A/E1B-deleted helper adenovirus;
(4) efficient packaging of both single-stranded and double-stranded (self-complementary) AAV vectors; and (5)
efficient packaging of large AAV cassettes such as a mini-dystrophin vector (5.0 kb). All cell lines were stable
with growth rates identical to the parental 293 cells. The vector yields were consistent among serotypes, with
51013 to 81013 vector genome particles per Nunc cell factory (equivalent to 40 15-cm plates). The vectors
showed high potency for in vitro and in vivo transduction. In conclusion, the simple and versatile AAV producer
cell line method can be useful for large scale AAV vector production in preclinical and clinical studies.
Introduction
Adeno-associated virus (AAV) vectors are commonlyused as a powerful tool for in vivo gene transfer studies.
They have been successfully tested in animal models to es-
tablish efficient and long-term gene transfer in a variety of
tissues and bodywide without apparent toxicities. The success
of preclinical studies has led to clinical trials using AAV
vectors to treat genetic diseases such as hemophilia (Mar-
garitis and High, 2010), muscular dystrophy (Wang et al.,
2000; Chamberlain, 2002; Mendell et al., 2009, 2010a,b), Le-
ber’s congenital amaurosis (Maguire et al., 2008, 2009), and
alpha-1 antitrypsin deficiency (Brantly et al., 2009). Although
the applications of AAV vectors offer great potential for many
genetic diseases, current vector production methods still have
room for improvement to meet the demands of clinical studies
involving certain genetic diseases, particularly those that re-
quire large quantities of high-quality vectors. For example,
gene therapy for muscular dystrophies requires whole-body
gene transfer in muscle, which is the largest organ in the body.
This prompted us to develop a high-yield, scalable production
method to meet the demands.
For AAV vector production, a number of strategies dif-
fering in principles are being used (Wang et al., 2003). The
most widely used is based on the helper-virus–free transient
transfection method with all cis and trans components (vec-
tor plasmid and packaging plasmids, along with helper
genes isolated from adenovirus) in host cells such as 293 cells
(Xiao et al., 1998; Lock et al., 2010). While the transient-
transfection method is simple in vector plasmid construction
and generates high-titer AAV vectors that are free of ade-
novirus, it is not cost effective to scale up for clinical studies.
A second strategy is the recombinant herpes simplex virus
(rHSV)-based AAV production system, which utilizes rHSV
vectors to bring the AAV vector and the Rep and Cap genes
into the cells (Wu et al., 2002; Clement et al., 2009; Kang et al.,
2009).The third method based on baculovirus system
was developed in recent years and requires simultaneous
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infection of insect cells with several baculovirus vectors to
deliver the AAV vector cassette and the Rep and Cap genes
(Urabe et al., 2002; Kohlbrenner et al., 2005; Meghrous et al.,
2005). For both the rHSV- and baculovirus-based AAV pro-
duction systems, it is inconvenient to prepare large quantities
of helper and vector viruses and maintain their purity and
stability. The fourth method is based on the AAV producer
cell lines derived from HeLa or A549, which stably harbored
AAV Rep/cap genes. The AAV vector cassette was either
stably integrated in the host genome (Clark et al., 1995) or
introduced by an adenovirus that contained the cassette
(Chadeuf et al., 2000; Wang et al., 2003). Although the cell line
method is easy to scale up and produces relatively high titers
of AAV vectors comparable to transient transfection method,
these cell lines required wild-type adenovirus as the helper.
Contamination of wild-type adenovirus in the final vector
preparations is highly undesirable in view of vector safety.
To eliminate transient transfection step and avoid the use
of wild-type helper adenovirus, we established AAV pro-
ducer cell lines based upon the human 293 cells. These cells
contain highly inducible AAV Rep and Cap genes and also
the adenovirus E1A/E1B genes, able to use E1A/E1B-
defective adenovirus for helper functions. Considering that
E1A/E1B-defective adenovirus has been widely used as a
gene therapy vector in humans, its safety profile is better
than the wild-type adenovirus. However, the major difficulty
in generating a 293-based AAV producer cell line is the E1A-
mediated activation of AAV promoters p5 and p19, which
control AAV Rep proteins. The latter are known to be cyto-
static (Yang et al., 1994) and even cytotoxic (Schmidt et al.,
2000) if constantly expressed. Additional difficulties in gen-
erating tightly regulated p19 is its location within the coding
region of Rep78 and Rep68 (Im and Muzyczka, 1990). Pre-
viously, we developed a novel gene expression control sys-
tem, termed dual slicing switch system, where an intron and
three polyadenylation elements were inserted into the Rep
gene-coding region disrupting all Rep transcripts. Upon in-
duction of AAV Rep gene expression by Ad-cre (an E1A/
E1B/E3-deleted adenovirus expressing the Cre gene), both
DNA splicing by Cre-loxP and RNA splicing to remove the
intron (dual splicing) reconstitute and activate Rep gene ex-
pression in the AAV producer cell lines. By using this tightly
controlled system, we have successfully obtained the 293-
based AAV packaging cell lines with both high stability and
high vector yields (Qiao et al., 2002b). The 293 cell–based
AAV packaging cell lines had higher or equivalent vector
yields compared with the transfection method (Xiao et al.,
1998) and HeLa cell–based lines (Clark et al., 1995; Qiao et al.,
2002a).
There are several advantages to utilizing our previous 293-
based cell lines, including high infectivity, high yields, and
the capacity to scale up. However, a chief limitation is the
multi-step and time-consuming procedure. Due to two steps
of transfection and selections, several weeks to months are
needed to produce a high-yield cell line (Qiao et al., 2002b).
To establish our previous AAV producer cell line, the first
step was to deliver the inducible Rep/Cap plasmid to the 293
cells to screen for parental inducible 293-Rep/Cap cell line
without AAV vector sequences. The second step was to in-
troduce the AAV vector component and additional copies of
the inducible Rep and Cap genes to the Rep/Cap inducible
parental cell line by using a different drug-resistant selection
marker. Another limitation of this method is the large size of
the second plasmid, which makes it very inconvenient to
clone various vector cassettes into it due to very few choices
of restriction enzyme sites.
To overcome these limitations, we took advantage of the
Gateway cloning technology (Suzuki et al., 2005) to simplify
the cloning process. We also omitted the first step of parental
AAV Rep/Cap cell cloning in the original protocol (Qiao et al.,
2002b) and directly used the single plasmid containing the
inducible Rep/Cap genes and AAV vector elements and a drug-
resistant marker for a single transfection and selection step.
This shortened more than half of the work load and process
time. Furthermore, we have successfully tested the 293-based
cell line strategy with different serotypes including AAV8 and
AAV9 in addition to AAV2. Finally, these cell lines were found
efficient in producing both single-stranded AAV(ssAAV) and
double-stranded AAV(dsAAV) vectors. The improved meth-
od will provide a versatile and scalable AAV production
system for preclinical and future clinical applications.
Materials and Methods
Construction of large plasmid for cell line
establishment using Gateway system
The pENTR11 (Invitrogen, Carlsbad, CA) was chosen as
the entry plasmid. To clone the AAV vector sequence into
this plasmid, two restriction endonucleases that cut on op-
posite sites of the ccdB selection marker gene were used to
replace the AAV vector sequence. For the construction of
single-stranded AAV vector entry plasmid, the fragment
containing the inverted terminal repeats (ITRs) and cyto-
megalovirus–green fluorescent protein (CMV-GFP) cassette
was excised from pUF1-CMV-GFP (Wang et al., 2003) by
Sse8387I digestion and filled in by Klenow enzyme, and then
inserted into the pENTR11 plasmid, generating plasmid
pENTR11-ss-CMV-GFP. For the construction of double-
stranded AAV vector entry plasmid, the fragment containing
the ITRs and CMV-GFP cassette was excised from the
pdsAAV-CMV-GFP (Wang et al., 2003) plasmid by SwaI þ
EcoO109I double digestion and inserted into the PENTR11
plasmid, generating plasmid pENTR11-ds-CMV-GFP (Fig.
1a). For the construction of entry plasmid harboring the
optimized human mini-dystrophin gene, plasmid pAAV-
CMV-Opti-hDys3978 was digested by SwaI and ScaI, the
fragment containing the CMV-hDys3978 flanked by ITRs
was inserted between the XmnI and EcoRV site of pENTR11
vector to replace the ccdB gene, and therefore the entry
plasmid pENTR11-CMV-opti-hDys3978 was obtained.
The pXX2-Int-3A-Puro (Qiao et al., 2002b) was chosen as a
packaging backbone construct harboring the inducible Rep/
Cap genes. A single restriction site of NgoMIV located in the
noncoding area in this plasmid was utilized for insertion of
recombination sites and and chloramphenicol resistance gene
(CmR). The blunt end conversion cassette from the Gateway
conversion kit (Invitrogen) (Campeau et al., 2009) was in-
serted into the NgoMIV site of the pXX2-Int-3A-Puro fol-
lowing the manufacture’s protocol. The conversion cassette
contains ccdB gene flanked by attR1 and attR2 site. Briefly,
pXX2-Int-3A-Puro was first digested with NgoMIV and then
blunted using Klenow fragment, and the linearized vector
was then treated with calf intestinal alkaline phosphatase to
prevent self-ligation. Subsequently, a ligation reaction was
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performed to insert the conversion cassette into the vector.
After transforming the ligation product into an special E. coli
strain (ccdB SurvivalTM 2 T1R Competent Cells, which tol-
erate the ccdB gene) (Invitrogen) and selecting the recombi-
nant clone on the Luria-Bertani (LB) plates containing 30 mg/
ml chloramphenicol and 50 mg/ml ampicillin, the destination
plasmid pSPG2 for AAV2 was obtained (Fig. 1b). To con-
struct the destination plasmid for establishment of other se-
rotype AAV, the AAV2 Cap gene was replaced by Cap gene
of other serotype AAV (for example: AAV8 or AAV9), and
the obtained plasmid was named as pSPG8 or pSPG9, re-
spectively.
To construct the inducible packaging plasmid for the es-
tablishment of cell line of a specific AAV serotype and
FIG. 1. Plasmids construction and illustration of site-specific homologous recombination in the Gateway system. (a)
Construction of the entry plasmid PENTR11-D(þ)-CMV-GFP. The ccdB gene in pENTR11 was replaced by CMV-GFP-pA
cassette flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs) from pAAV-D(þ)-CMV-GFP. CMV,
cytomegalovirus; GFP, green fluorescent protein. (b) Construction of the destination (packaging backbone) plasmid pSPG2.
The reading frame cassette containing the chloramphenicol resistance gene (CmR) and the ccdB gene flanked by attR1 and
attR2 sites was inserted into the NgoMIV site of plasmid pXX-Int-3A-Puro to generate the destination plasmid pSPG2. (c) The
schematic diagram demonstrating the efficient generation of the inducible packaging plasmid by recombination of the
destination plasmid pSPG and the entry plasmid pENTR11-AAV mediated by the LR clonase II. As a result, the large
inducible packaging plasmid containing inducible rep, cap genes, and AAV vector sequences was obtained.
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vector, the ITR-containing vector cassette in a given entry
plasmid was recombined efficiently into the destination
plasmid of specific serotypes via the attL-attR(LR) recombi-
nation reaction. The recombinant product was then trans-
formed into DH10B competent cells and plated onto LB agar
plate containing 100mg/ml ampicillin. Notably, the Entry
and Destination vectors carried different drug resistance
genes for selection in E. coli, kanamycin for the entry vector,
and ampicillin for the destination vector. The parental des-
tination plasmid contained ccdB gene and could not grow in
DH10 strain. After recombination, the ccdB gene was re-
moved from the destination vector and the recombined in-
ducible packaging plasmid would grow in DH10B. As an
example, recombination of pENTR11-ds-CMV-GFP and
pSPG2 gave rise to an inducible plasmid named as pSPG2-
ds-CMV-GFP (Fig. 1c), which was used for the establishment
of dsAAV2-CMV-GFP–producing 293 cell line. By using the
same strategy, we obtained a series of plasmids for the es-
tablishment of 293-based cell line producing different sero-
types of ssAAV and dsAAV.
Cells and virus
Ad-GFP, an adenoviral vector harboring an EGFP gene
under the control of CMV promoter, and Ad-Cre, an ade-
noviral vector harboring the Cre recombinase gene of P1
phage driven by CMV promoter, were acquired by a con-
ventional method. These adenoviruses were E1A/E1B- and
E3-defective first-generation adenoviral vectors ( Jiang et al.,
2001).
293 Cell lines were propagated in Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen) supplemented with
heat-inactivated 10% fetal bovine serum (FBS; Invitrogen)
and antibiotics. Stable transfection was performed in 293
cells by the calcium phosphate transfection method as
previously described (Xiao et al., 1998). Briefly, the 293
cells were passed into a six-well plate at 1:4 ratio (area to
area) with each well containing 1.5 ml of fresh DMEM
supplemented with 10% FBS without antibiotics 1 day
before transfection. The pSPG plasmid (3 mg) was linear-
ized by AseI digestion followed by DNA precipitation. The
linearized plasmid was dissolved in 10 to 20 ml of TE (pH
7.0) and added to an eppendorf tube containing 0.25 M
CaCl2 and then quickly mixed with 125 ml of 2X HEPES-
buffered saline and added to the 293 cells. At 12 hr after
transfection, the medium was replaced with fresh DMEM
containing 10% FBS and 2 mg/ml puromycin (Sigma). The
transfected cells were trypsinized 48 hr later, serial di-
luted, and plated onto 15-cm-diameter dishes to allow for
the growth of single-cell clones. The clones were picked
using pipette and transferred to 12-well plate for contin-
uous culture. To test the vector productivity of the cell
lines, the helper Ad-cre at a multiplicity of infection (MOI)
of 5 was added to the cells at confluence of 80%–90%. The
cells and the supernatant were harvested 48 hr after in-
fection and subjected to three freeze–thaw circles to release
the AAV from cells and then incubated in the 568C water
incubator for 1 hr to inactive the helper Ad-cre virus. The
titers of the vectors from each clonal celll lines were de-
termined by the standard vector DNA dot blot method
(Xiao et al., 1998) or by infection on 293 cells if the vector
contained the GFP reporter gene.
AAV vector production and purification
For the production of AAV2, 8 and 9 from the inducible
293-based cell lines, the cells were simply infected with Ad-
Cre at MOI of 5. At 2 days after infection, cells from 20 15-cm
plates were pelleted by centrifugation and resuspended in
suspension buffer (phosphate-buffered saline [PBS] with
25 mM HEPES and 150 mM NaCl). The viral particles were
purified twice by cesium chloride density gradient ultra-
centrifugation, using the previously a published protocol
(Ayuso et al., 2010). Vector titers were determined by the
DNA dot-blot method.
To validate whether the cell line could retain a similar
productivity while scaling up, Nunc Cell Factories (Nalge
Nunc International, Roskilde, Denmark) were used to scale
up the culture of the cell line for production of AAV9-CMV-
Opti-hDys3978 vector according to the manufacturer’s in-
structions. Each Nunc Cell Factory is equivalent to 40 15-cm
plates. Ad-Cre infection, subsequent harvesting, and purifi-
cation procedures were carried out similar to those described
above.
Quantification of Rep gene copy number
by using real-time polymerase chain reaction
For the quantification of Rep gene copy number in stable
293-based cell lines, we used SYBR green–based real-time
quantitative assay (ABI PRISM 7700 Sequence Detector,
Applied Biosystems, Foster City, CA). We designed the
primers to amplify a 317-bp fragment of the Rep gene. The
sequences of the forward and reverse primer are: rep-50: 50-
GGG ATT ACC TCG GAG AAG CAG TGG-30; and rep-30: 50-
CTT CCC GGT AGT TGC AGG-30. We also designed the
primer to amplify a 300-bp fragment of the human glucagon
gene as the internal cell copy number control. Sequences of
the forward and reverse primers are as follows: human-
glucagon-F: 50-TGA GAG ACA TGC TGA AGG GAC-30;
human-glucagon-R: 50-CTT TCA CCA GCC AAG CAA TG-30.
Total cellular DNA was extracted from cells by using the
DNeasy Tissue Kits (Qiagen, Valencia, CA). Copy numbers
of the Rep gene detected by real-time polymerase chain re-
action (PCR) were reported as Rep copies per cell.
Mice, AAV vectors administration,
and immunostaining of dystrophin
The mdx mice were purchased from Jackson Laboratory
(Bar Harbor, ME) and the animal protocols were approved
by the Animal Care and Use Committee of University of
North Carolina at Chapel Hill. The mdx mice (3-month-old
males) were divided into two groups. One group was treated
with the AAV9-CMV-opti-hDys3978 vector produced from
the producer cell line, while the other group was given the
same dosage of the AAV9-CMV-opti-hDys3978 produced by
the triple plasmid transfection method. Specifically, 2.51010
vector genome (vg) (50 ml) of AAV vectors and 41010 vg
(80 ml) of AAV vectors were directly injected into the tibialis
anterior (TA) muscle and gastrocnemius (GAS) muscle re-
spectively. Four weeks post injection, the mice were sacri-
ficed and the injected muscles were carefully dissected and
cryo-preserved. Then the muscle tissues were subjected to
cryosectioning and immunofluorescent (IF) staining. The
protocol for the IF analysis used here was described previ-
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ously (Watchko et al., 2002). The primary polyclonal anti-
body (rabbit serum anti-human dystrophin R22 and R23
regions, 1:500) was produced in Xiao Xiao’s lab, and the
secondary antibody (Cy 3-conjugated AffiniPure Goat anti-
Rabbit IgG, 1:500) was purchased from Jackson Im-
munoResearch (West Grove, PA).
Neutral and alkaline gel electrophoresis of AAV DNA
To extract DNA from the purified AAV vector, 11011 vg
of purified AAV vector was diluted into a final volume of
100 ml of DMEM containing 2 U of DNase I and incubated at
378C for 30 min to digest any residual plasmid DNA. Then
100 ml of 2proteinase K buffer (20 mM Tris-HCl pH 8.0,
20 mM EDTA pH 8.0, 1% SDS) and 2ml of proteinase K
(20 mg/ml) were added and incubate at 558C for 30 min. The
AAV DNA was then precipitated by ethanol precipitation.
The final DNA was dissolved in 50ml of double-distilled
H2O.
For neutral gel electrophoresis, the AAV DNA was run on
regular 1% agarose gel. Alkaline gel electrophoresis of AAV
DNA was performed according to the method described in
published literature (McDonell et al., 1977).
Results
Construction of vector shuttle and packaging backbone
plasmids using Gateway system
One of disadvantages of our previous system is that the
size of the final plasmid for establishing a cell line is very
large. It has very few convenient restriction enzyme sites to
choose for subcloning the vectors with different reporter or
therapeutic genes. To address this problem, we employed
the Gateway system (Invitrogen) to facilitate the plasmid
construction. Compared with traditional DNA cloning,
Gateway cloning technology provides a rapid and efficient
way for gene cloning into larger size plasmids without the
requirement of restriction enzymes and gel purification and
ligation steps (Suzuki et al., 2005).
First, we constructed a vector shuttle plasmid for AAV
vector cassette (Fig. 1a). The plasmid contained Gateway attL
recombination sites flanking the ITRs of the AAV vector.
Shown in Fig. 1a is an example of constructing the vector
shuttle plasmid for double-stranded AAV-CMV-GFP
(dsAAV-CMV-GFP) vector (see Materials and Methods for
details). The plasmid pENTR11-ds-CMV-GFP is ready to be
recombined with the inducible Rep/Cap-containing plasmid
below.
Next, we constructed a packaging backbone plasmid
containing attR recombination sites for the shuttle vector
plasmid to be recombined into. More importantly, the
backbone plasmid contained the inducible Rep gene of AAV2
and Cap gene from different serotypes, e.g., AAV2, 8 and 9,
respectively. Shown in Fig. 1b is an example of AAV2
packaging backbone plasmid. In detail, an open reading
frame cassette containing the chloramphenicol resistance
gene (CmR) and the ccdB gene flanked by attR1 and attR2
sites were inserted into the NgoMIV site of plasmid pXX-Int-
3A-Puro, which is an AAV2 inducible Rep/Cap plasmid
(Qiao et al., 2002b).
Finally, we recombined the vector shuttle plasmid and
packaging backbone plasmids to obtain the final inducible
vector and packaging plasmid for the generation of 293 cell
lines (Fig. 1c). This step had no enzyme digestion and liga-
tion involved. After recombining the vector shuttle plasmid
pENTR11-ds-CMV-GFP with packaging backbone plasmid
pSPG2 in the test tube by LR Clonase II, the recombination
product was transformed into the DH10B competent E. coli
cells and selected on the plate containing Amp antibiotics.
The recombination efficiency was greater than 95% mainly
due to the negative selection marker ccdB gene and different
antibiotic resistant gene selection.
By utilizing the Gateway system, it was much easier for
us to establish an inducible AAV plasmid containing dif-
ferent promoters, genes of interest, and alternative AAV
serotypes. For example, only the vector shuttle plasmid
needs modification for new promoter and new genes of
interest. Similarly, only the packaging backbone plasmid
needs to be modified to obtain the Cap gene of different
AAV serotypes.
Generation of stable and high-titer 293 cell–based
dsAAV2 cell line by one-step strategy
Previously, two steps of transfection and selection were
required to establish the high-yield AAV-producer 293 cell
lines. Here we used the one-step procedure with the final
plasmid pSPG2-ds-CMV-GFP containing inducible AAV2
packaging genes, AAV2 ITRs, and CMV-GFP reporter gene
cassette. One of the ITRs contained the deletion of the D-
sequence and therefore enabled production of dsAAV (Wang
et al., 2003). This plasmid was transfected into 293 cells and
selected for puroR-resistant colonies. Among 48 clones tested
for productivity, more than 10 of them demonstrated AAV
vector yields of >109 transducing units (TU, GFP-positive
cells) from each 10-cm plate of producer cells (equivalent to
200 TU/cell). The yield of one cell line, the 293-dsGFP-12,
was as high as 9109 TU per 10-cm plate (81011 vg,
equivalent to 1.6105 vg/cell). Optimization of helper Ad-
Cre MOI ranging from 0.1 to 20 showed that MOI of 5 was
optimal for AAV vector production (Fig. 2). Furthermore, the
AAV packaging cell lines were very stable with normal
growth rate and morphology indistinguishable from the
parental 293 cells (Fig. 3). Importantly, the productivity also
remained the same after consecutive multiple passages (data
not shown), consistent with our previously published data
(Qiao et al., 2002b).
Generation of 293-based cell lines
for AAV serotypes 8 and 9
Our previous cell lines were all AAV2 vector producers
mainly because it was the most used serotype at the time
(Clark et al., 2005; Qiao et al., 2002a). However, lower effi-
ciency of gene transfer in vivo and high prevalence of pre-
existing immunity have hampered the use of AAV2-based
vectors (Gao et al., 2000). Novel serotypes and engineered
AAV capsids (Gao et al., 2002; Yang et al., 2009) have been
generated and explored, including AAV8 and AAV9.
To establish AAV8 and AAV9 cell lines, we modified the
AAV2 packaging plasmid pSPG2 and replaced the AAV2
Cap gene with that of AAV8 or AAV9, generating pSPG8 and
pSPG9, respectively (Fig. 1c). By recombination of these pack-
aging backbone plasmids with the vector shuttle plasmid, we
AAV PRODUCER CELL LINES OF DIFFERENT SEROTYPES 617
obtained the inducible vector and packaging plasmids for the
production of AAV8 and AAV9 vectors. Following the same
procedure for the establishment of the AAV2 producer cell
lines, cell lines for the production of dsAAV8-CMV-GFP and
dsAAV9-CMV-GFP were established.
Creating the 293-based cell line packaging
a large-sized gene
Previous attempts to generate high-titer AAV-mini-dys-
trophin vector with a baculovirus-based system were not
successful, possibly due to the oversize of the vector (un-
published data), which was around 5 kb and slightly over the
size of the wild-type AAV (4.8 kb). Here we tried to generate
high-yield AAV producer cell line for the mini-dystrophin
construct. We cloned the AAV-CMV-Opti-hDys3978 vector
cassette into the vector shuttle plasmid containing attL re-
combination sites. The shuttle plasmid was recombined with
the pSPG9 plasmid to generate the final inducible AAV9
packaging plasmid pSPG9-CMV-opti-hDys3978. As de-
scribed before, the AAV9-CMV-Opti-hDys3978 cell line
clones were randomly picked and subjected to productivity
test by using dot blot assay. Among the 48 cell clones tested,
more than 10 yielded greater than 11012 vg per 10-cm plate
(equivalent to 2105 vg/cell). One of them, 293-Dys3978-14,
yielded as high as 2.61012 vg per 10-cm plate (equivalent to
5.2105 vg/cell) and was then selected for large-scale pro-
duction.
To test whether the cell line can be adopted to the scalable
production, Nunc cell factory (equals to 40 of 15-cm plates)
was used to culture three cell lines (293-dsAAV2-GFP-12,
293-ssAAV2-GFP-145, 293-ssAAV9-Dys3978-14). After the
purification of the AAV vector from the cell line, the pro-
ductivity for each cell line was analyzed by dot blot assay.
These cell lines showed similar productivity in Nunc cell
factory as in plates. The yield of each cell line was about
51013 to 81013 vg particles per Nunc cell factory (equiv-
alent to 0.9105 to 1.3105 vg/cell) (Table 1).
Amplification of Rep/Cap genes in high-yield
producer cell lines upon Ad helper infection
To investigate the relationship of cell line productivity
with the Rep/Cap gene copy number integrated in cells, the
Rep/Cap gene copy numbers in several 293-based cell lines
were quantitatively determined by using real-time PCR
technology (Table 2). The range was between 10 and 50
copies per 293 cell. We did not find an obvious relationship
between the integrated Rep/Cap gene copy number and
vector productivity. We have previously documented that
the Rep and Cap genes were amplified during the vector
production phase, upon Ad-Cre helper virus infection of the
FIG. 2. Optimization of the multiplicities of infection (MOI)
of Ad-Cre for the production of AAV2-D(þ)-CMV-GFP from
cell line 293-DsGFP-12. Different groups of cells were cul-
tured in 10-cm plate (n¼ 4 for each group). At 70% to 90%
confluence, the cells were infected with different MOI of Ad-
Cre. When clear CPE was evident at around 48 hr post in-
fection, all the cells were harvested and centrifuged at
2000 rpm for 10 min. Then the supernatant was removed and
1 ml of virus suspension buffer (see Material and Method for
details) was added to the pellets, which contained AAV
vector and Ad-Cre virus. After three freeze–thaw cycles in a
dry ice–ethanol bath, tubes were subjected to centrifugation
again and the supernatant containing final viruses were used
for titration. All the viruses were incubated at 56 for 30 min
to inactivate Ad-Cre before titration. The yield of the cell line
was determined by quantifying the transduction unit per
production cell (TU/cell). Mean values and standard devia-
tions are displayed in the figure.
Table 1. Vector Yields From Different Cell
Lines via Large-Scale Production
a








aThe Nunc cell factory (equivalent to 40 15-cm plates) was utilized
to scale up AAV production based upon cell lines. Ad-Cre infection
and sebsequent AAV vector harvesting and purification processes
were carried out as described in Material and Methods. vg, vector
genome.
FIG. 3. The doubling time of 293-dsAAV2-GFP-12 cell line
at passages 5 and 20. The parental 293 cell line was used as a
control. Both cell lines were seeded in a six-well plate at a
plating density of 5105 cells per well and cultivated in a cell
incubator. Every 24 hr (i.e., 24, 48, 72 post seeding), three
wells of each kind of cell were used to determine the cell
numbers by counting the cells using a hematocytometer. The
cell doubling time was calculated using the algorithm pro-
vided by http://www.doubling-time.com/compute.php?
lang¼en
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producer cells (Qiao et al., 2002b). However, the previous
producer cells contained high-copy number of Rep and Cap
genes that were introduced separately by two rounds of
stable transfection and selection. It is unclear which com-
ponent (or both) was amplified during the production phase.
To see if the Rep and Cap genes were also amplified in the
new generation producer cells that contained the genes in-
troduced at a single time, we analyzed the Rep and Cap copy
numbers in those cell lines before and after Ad-Cre infection.
Quantitative real-time PCR analysis was performed on the
total DNA extracted from those cells. As shown in Fig. 4a,
Rep/Cap gene of 293-dsAAV2-GFP-12 was amplified around
14-fold, starting from 17 copies per cell to approximately 236
copies at 48 hr after Ad-Cre infection. Similarly, amplification
of Rep/Cap genes was also observed in the other 293-based
cell line, such as single-stranded AAV packaging cell line, the
293-ssAAV2-GFP-145 cells (Fig. 4a); AAV8 producer cells,
the 293-dsAAV8-GFP-23 (Fig. 4b); and the AAV9 producer
cells, the 293-dsAAV9-GFP-34 (Fig. 4b). In general, the in-
ducible Rep/Cap genes were amplified 10–20 times after Ad-
Cre infection. Importantly, this amplification was dependent
on the activation of Rep gene by Ad-Cre. The same cell line
infected with Ad-GFP and wild-type adenovirus did not
achieve any amplification of the AAV Rep/Cap genes (Fig. 4b)
because these two helper Ad could not activate the Rep gene
that had three polyA sites inserted in the middle of the
coding region (Fig. 1). These results show that amplification
of the Rep and Cap genes is responsible in part for the high
vector yields in the cell lines.
Characterization of AAV vectors from
cell lines in vitro and in vivo
We next examined the cell line–produced vectors for their
infectivities in vitro and in vivo, wild-type–like AAV contam-
ination, and the integrity of the virus genome, particularly for
the double-stranded vectors. The ratios of viral genome par-
ticles versus the transducing units (vg/TU) is usually used as
an indicator of AAV2 vector infectivity in vitro. We thus
compared the vg/TU ratio of dsAAV2-GFP vectors produced
by the methods of cell lines or triple-plasmid transient trans-
fection side by side. The vg titer was determined by vector
DNA dot blot, whereas the TU titer was determined by in-
fecting 293 cells in the absence of adenovirus. Our results
showed that the ratio of vg/TU of AAV2 vectors produced
from the 293-DsGFP-12 cell line was 85.4 11.2, whereas the
ratio of the vg/TU of AAV2 vectors derived from the triple
transfection method was 480.8 67.2. Additionally, we per-
formed in vitro infection assay to compare the transduction
efficiency of the viruses produced from different methods. As
shown in Fig. 5a, both AAV2 and AAV9 vectors produced
from cell line method demonstrated better infectivity than the
Table 2. Integrated Rep Gene Copy Numbers in 293-Based Cell Lines and Vector Yieldsa




293-ssAAV2-GFP-145 ssAAV2-CMV-GFP 34 1.63 2.81013
293-dsAAV2-GFP-12 dsAAV2-CMV-GFP 17 4.74 2.01013
293-dsAAV8-GFP-23 dsAAV8-CMV-GFP 28 3.56 1.21013
293-dsAAV9-GFP-34 dsAAV8-D(CMV)-GFP 23 3.23 1.51013
293-ssAAV9-Dys3978-14 dsAAV9-CMV-hDys3978 36 5.25 2.51013
aThe copy numbers displayed in the table were those in the stable cell lines before Ad-Cre infection. SYBR Green–based real-time PCR
methods were utilized here (see Material and Methods for details).
FIG. 4. The amplification of Rep gene after Ad-cre infection
in 293-based AAV producer cell line. (a) Real-time PCR
analysis of AAV rep gene amplification in cell lines produc-
ing double-stranded AAV2-ds-CMV-GFP vector (solid col-
umn) and single-stranded AAV2-CMV-GFP (open column)
at different time points post Ad-Cre infection at MOI of 5.
Total cellular DNA was extracted from different cell lines at
different time point post Ad-Cre infection, then real-time
PCR was performed to determine the rep gene copy num-
bers. The final copy number was calculated as (vector copy
numbers/human glucagon gene internal control)2. (b)
Real-time PCR analysis of AAV rep gene amplification in cell
lines producing AAV2-ds-CMV-GFP, AAV8-ds-GFP, and
AAV9-ds-GFP. The Ad-Cre, Ad-GFP and wild-type adeno-
viruses were utilized at an MOI of 5, and the viruses were
harvested at 48 hr post infection.
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FIG. 5. Characterizaiton of AAV vectors produced from cell lines in vitro. (a) Comparison of the transduction efficiency of
AAV vectors produced by the transfection method or cell line method. 293 Cells were used for the AAV2 vector transduction
efficiency test. U87 cells were used for the AAV9 vector. Original magnification100. (b) Real-time quantitative PCR analysis
of replication competent AAV (rcAAV) in different AAV GFP vectors. The primers were the same as described in quanti-
ficaiton of Rep gene copy numbers in Material and Methods. Up to 109 viral genome particles of highly purified AAV vectors
produced from different methods were used to infect 10-cm plates of 293 cells, which were coinfected with wild-type
adenovirus at an MOI of 5 to provide helper function for rcAAV amplification. As a positive control, wild-type AAV was also
used to infect the 293 cells at a total dose ranging from 1 to 10 infectious units per 10-cm plate along with wild-type
adenovirus coinfection. (c) Electrophoresis of vector DNA produced from the cell line and transfection methods on the
neutral gel. Two double-stranded vectors, AAV2-ds-GFP and AAV9-ds-GFP, produced from cell lines displayed double-
stranded hairpin of 2.2 kb on neutral gel, similar to the dsAAV genome DNA generated from the transfection method. (d)
Electrophoresis of vector DNA on alkaline gel. The dsAAV hairpin DNA from different methods was denatured into a 4.4-kb
linear ssDNA. No detectable linear single-stranded monomers of 2.2 kb were present in the alkaline gel, indicating that most
of the packaged genome in dsAAV particles is the dimer hairpin DNA. Color images available online at www.liebertonline
.com/hum
620 YUAN ET AL.
double-stranded vectors produced from transfection method,
which is consistent with the previously published data on
ssAAV2-GFP vectors (Qiao et al., 2002b).
Since the generation of replication-competent AAV (rcAAV,
also termed wild-type–like AAV) is a potential safety concern
for clinical applications of AAV vectors, we set out to examine
the wild-type–like AAV in the cell line–produced AAV vec-
tors using the quantitative real-time PCR method. We chose to
use an infection-based viral amplification assay with wild-
type adenovirus helper to detect the rcAAV (Qiao et al.,
2002b). Real-time PCR analysis of the viral DNA isolated after
two rounds of amplification in 293 cells revealed no detectable
AAV coding sequences (similar to background level) from the
AAV vector stocks produced by both cell line and triple plas-
mid transduction methods (Fig. 5b). These results indicate that
there is no detectable rcAAV in up to 109 viral genome par-
ticles of AAV vector produced by the 293-based cell lines.
We also examined the integrity of the scAAV genomes
produced by the cell line method, since other labs have re-
ported that a mixture of double-stranded and single-stranded
genomes could be packaged into AAV virons during the
process of vector production even using a transient transfection
method (Wu et al., 2002). In addition, an HSV helper system
was unable to produce the scAAV vectors without a vast
majority of the vector DNA genomes being in the ss form
when assayed on alkaline denature gel (Wu et al., 2002). To
confirm that the AAV genomes packaged in the scAAV vectors
derived from the 293-based cell line were indeed predomi-
nantly in the hairpin-like self-complementary form as observed
before (Wang et al., 2003), the DNA extracted from both single-
and double-stranded vectors produced from cell lines was
subjected to neutral and alkaline gel electrophoresis. On neu-
tral agarose gel, the dsAAV DNA produced from both AAV2
and AAV9 cells lines displayed a double-stranded hairpin of
2.2 kb, similar to the dsAAV genome DNA generated from
transfection method (Fig. 5c). Consistently, the dsAAV hairpin
DNAs were denatured into a 4.4-kb linear ssDNA when run-
ning on the alkaline agarose gel (Fig. 5d). No significant linear
single-stranded monomers of 2.2 kb were present in the alka-
line gel, indicating that the vast majority of the packaged ge-
nome in dsAAV particles from both production methods were
indeed in the form of double-stranded hairpin DNA.
Finally, we analyzed the vector infectivity in vivo. AAV9-
CMV-Opti-hDys3978 vectors produced by the transfection
method or cell line method were directly injected in dystro-
phin-deficient mdx mice in the TA muscle (2.51010 vg of
vector in 50 ml) and GAS muscle (41010 vg of vector in
80ml), respectively. The treated mice were sacrificed 4 weeks
post delivery. Dystrophin expression was evaluated by im-
munofluorescent staining on cryo-thin sections of the mus-
cles. Greater than 80% of the myofibers in the TA and GAS
muscles of mdx mice injected with vector from cell line
method showed strong dystrophin staining, similar to the
muscles injected with AAV9-CMV-Opti-hDys3978 made by
triple transfection method (Fig. 6). This result suggests that
the vector produced from our 293-based cell line is also
highly infectious in vivo.
Discussion
To meet the demand for high quality and large quantity
AAV vectors required in preclinical large animal studies and
for clinical trials, extensive efforts have been made to
improve the methodology for AAV production. We have
previously made strides in developing the first stable 293-
cell–based high yield AAV2 producer cell lines. In addition
to the avoidance of the transient tranfection step during
vector production, the major advantage of using the 293-
based cell line is the ability to avoid the use of wild-type
adenovirus as the helper. However, the major drawback of
FIG. 6. Analysis of the potency of the AAV9-CMV-opti-hDys3978 vector produced from cell line in vivo. The AAV9-CMV-
Opti-hDys3978 vectors produced from either transfection or cell line method were delivered into the tibialis anterior (TA)
muscle and gastrocnemius (GAS) muscle of mdx mice (three mice per group) via direct intramuscular (IM) injection. Three
weeks post vector delivery, the delivered muscles were harvested and cryo-preserved. The muscles were then subjected to
cryosectioning and immunofluorescent staining against dystrophin (see Material and Method for details). TA and GAS from
a normal B6 mouse and an mdx mouse without treatment were utilized as postive and negative controls. Original magni-
fication: 100. Color images available online at www.liebertonline.com/hum
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our previous method is the multiple steps of molecular
cloning for construction of a new vector and an alternative
serotype plasmid and the two-stage stable-transfection steps
to obtain the final AAV producer cell lines. In this study, we
streamlined the cloning process by using Gateway technol-
ogy, which utilizes site-specific recombination instead of
endonuclease and ligase to insert a gene of interest into an
expression vector. It offers two major advantages: first, the
recombination is efficient and rapid, making the cloning
process much easier especially for oversized vectors. Second,
it offers flexibility and convenience for swapping different
transgene cassette or using alternative serotypes for new
producer cells. In this study, we also established the 293-
based cell lines of a few different AAV serotypes using the
one-step transfection process. High-yield producers could be
consistently obtained with normal and stable growth rate
identical to their parent 293 cells. Thus, the improved and
simplified method can significantly save time and effort in
generating producer cell lines.
Using the simplified protocol, we have successfully es-
tablished 293-based high-yield AAV producer cell lines for
GFP-expressing vectors packaged in AAV2, AAV8, and
AAV9 capsids. The GFP vectors were also in the form of
double-stranded (self-complementary) DNA genomes. The
same GFP vector backbone, however, turned out to be very
difficult to produce with an HSV helper virus–based pro-
duction system (X. Wu, personal communication). The
dsAAV produced by the HSV system (Wu et al., 2002) con-
tained mostly ssAAV genomes when assayed on an alkaline
denaturing gel. For oversized AAV vectors, we had no dif-
ficulty in establishing high-yield cell lines, e.g., the cell line
producing AAV9-mini-dystrophin vector, which has a size of
over 5 kb. However, the same vector backbone did not
generate high-yield vector in the baculovirus system even
though a few attempts had been made. This was most likely
due to the large vector size or toxic sequence for baculovirus
(unpublished results and personal communications). To
carry out large-scale production, the cell line approaches
have distinct advantages with the use of bioreactors. For the
293-based cell lines, it is easy to adapt to suspension culture.
The technology for suspension culture of 293 cells has al-
ready been well established. Serum-free media for suspen-
sion culture are readily available from commercial sources.
Furthermore, in this study, we used the Nunc cell factory to
perform the large-scale AAV production. The productivity of
the cells cultured in Nunc cell factory remained similar to the
cells cultured in small plates, reaching to 51013 to 81013
vg/Nunc (equivalent to 0.9105 to 1.3105 vg/cell) after
purification, suggesting the productivity of the cell lines
were stable for scaling up.
To find out why the cell lines could produce high-yield
vectors, we looked at the copy numbers of the stably inte-
grated Rep/Cap genes and the copy numbers during vector
production. We found that the Rep/Cap genes in all of our cell
lines were amplified 10–20 times after Ad-Cre helper infection,
reaching several hundreds of copies per cell. This amplifica-
tion was only observed by infection with Ad-Cre for the in-
duction of Rep expression, but not by infection with Ad-GFP
or wild-type adenovirus. This finding indicated that the am-
plification was Rep protein dependent. The mechanism of the
application remains unclear, but it is possibly through the p5
promoter that was reportedly able to act as an origin for
limited DNA replication in a Rep-dependent manner (Fran-
cois et al., 2005). The amplification of the Rep/Cap genes was
observed in our previous 293 cell lines for AAV2 vectors (Qiao
et al., 2002b) and was also observed in HeLa-based wild-type
adenovirus-inducible AAV producer cell lines (Nony et al.,
2001; Tessier et al., 2001), suggesting that the amplification of
Rep/Cap gene may be essential to the higher productivity of all
AAV producer cell lines (Liu et al., 2000).
A chief advantage of the 293-based AAV producer cell
line over other cell lines is the use of replication-defective
adenovirus Ad-Cre, rather than the wild-type adenovirus.
The replication-defective E1-deleted adenoviral vectors have
been widely used for gene therapy in clinical settings for
vaccine and cancers and have shown a generally safe profile
in clinical trials aside from a single fatal adverse event more
than 10 years ago. Nevertheless, even the replication-
deficient adenovirus should be thoroughly inactivated and
eliminated from AAV preparations in view of safety and
immunity. The commonly used method is to thermally in-
activate the helper adenovirus. However, this method has
some drawbacks because it can not completely inactivate
the adenovirus. To address this problem, a novel method
using high hydrostatic pressure (HHP) to specifically and
completely inactivate helper adenovirus has been developed
(Leonard et al., 2007). This HHP method leads to thorough
elimination of adenovirus from the AAV preparations
without affecting AAV vector potency. Furthermore, utili-
zation of two-column chromotography purification sys-
tem should be effective in removing the helper adenovirus
(Gao et al., 2000). This easily scalable purification scheme
starts with cationic exchange chromatography to capture
AAV2 virions, followed by a purifying step with anionic
exchange chromatography, resulting in highly efficient
recovery of AAVs from crude lysates with substantially
improved purity and potency. Column purification methods
have also been sucessfully utilized for other AAV sero-
types such as AAV1 (Smith et al., 2008) and AAV8 (Davidoff
et al., 2004). The combination of our Gateway-mediated
single-step 293-based AAV producer cell line with the col-
umn chromatography purification system should facilitate
AAV vector production for preclinical and clinical applica-
tions.
Research in AAV-mediated gene therapy has been greatly
advanced over the last decade. Novel developments, such as
natural isolates of primate AAVs (Gao et al., 2002), direct
evolution of tissue-tropic AAV capsids (Maheshri et al., 2006;
Li et al., 2008; Yang et al., 2009; Asokan et al., 2010), and
double-stranded AAV vectors (McCarty et al., 2003; Wang
et al., 2003), have greatly expanded the potential of AAVs as
a gene therapy vector in a variety of clinical applications.
Future success in AAV-mediated clinical gene therapy re-
quires large-scale production of potent AAV vectors with
high titer and purity.
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